Home › Alzheimer's Disease › NCT03657745
Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy
An Observational Trial of Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy
Who can join
Ages 50 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Alzheimer's disease * Cognitive Impairment Exclusion Criteria: * any previously noted epileptic seizures, including febrile seizures. * any significant disease of the eye, such as macular degeneration. Since the 40Hz light therapy is delivered via eye stimulation, healthy eyes are required.
About the study
Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per second or 40Hz increased gamma brainwaves and led to clearing of beta amyloid plaques in the brain, a key abnormality in Alzheimer's disease. This project will test the ability of a novel iPad App (AlzLife https://www.alz.life/) that delivers light therapy at 40 Hz combined with cognitive therapy to improve cognition, function, and quality of life in Alzheimer's disease.
What is being tested
- Combination of 40Hz light and cognitive therapy (ALZLIFE) (device)
Sponsor: Alzheimer's Light LLC · Participants: 2,000 · Started: Jan 1, 2018
Contact the study team
- Andrey Vyshedskiy, Ph.D. · Phone: (617) 433-7724
Official record on ClinicalTrials.gov — NCT03657745
Locations in the U.S.
| Florida | Andrey Vyshedskiy, Miami |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.